For older adults with treatment-resistant depression, choosing an intervention involves more than determining which therapy produces the largest reduction in symptoms. New interventional psychiatry research examining ketamine vs ECT for geriatric depression highlights a more individualized question: which treatment offers the most appropriate balance of efficacy, speed, cognitive impact, medical burden, and durability for a particular patient?
A 2026 review by Lin and colleagues brings this question into focus by comparing the available evidence for ketamine and electroconvulsive therapy in late-life depression. The findings reinforce ECT’s established efficacy while identifying circumstances in which ketamine may offer a clinically meaningful alternative.
Why Late-Life Depression Requires A Different Treatment Calculation
Late-life depression can be especially difficult to treat. Older adults may have medical comorbidities, cognitive vulnerability, polypharmacy, reduced mobility, and greater sensitivity to treatment-related adverse effects. When conventional antidepressants fail, these factors can complicate decisions about advanced interventions.
ECT remains one of psychiatry’s most effective treatments for severe and treatment-resistant depression. Its role can be particularly important in patients with severe symptoms, psychotic depression, or illness requiring inpatient care.
The trade-offs are significant. ECT requires anesthesia and repeated treatment sessions, and cognitive adverse effects remain an important consideration. These factors can carry additional weight in older adults who already have concerns about memory, medical frailty, or the logistics of receiving treatment.
Ketamine vs ECT for Geriatric Depression Reveals Different Strengths
Ketamine approaches depression through a different biological pathway. Rather than primarily targeting monoamine neurotransmitters, ketamine acts through glutamatergic signaling and NMDA receptor modulation, initiating downstream processes associated with synaptic plasticity.
One of its defining clinical characteristics is speed. The review notes that ketamine studies have demonstrated meaningful antidepressant improvement within approximately 24 hours. ECT generally develops its therapeutic effect across a treatment course, but existing evidence supports stronger durability of remission in some populations.
This distinction makes the comparison more nuanced than identifying a single superior intervention.
Broader Evidence Still Supports A Strong Role For ECT
Previous meta-analyses comparing the two treatments have often favored ECT for acute depression outcomes. One systematic review of six clinical trials involving 340 patients found a greater overall reduction in depression severity with ECT than ketamine.
However, results have not been uniform across study designs and patient populations.
The large ELEKT-D comparative-effectiveness trial found intravenous ketamine to be noninferior to ECT for adults with nonpsychotic treatment-resistant major depression. The study also found different adverse-effect profiles, with ECT associated with musculoskeletal effects and ketamine associated with dissociation.
A subsequent analysis found that treatment setting and baseline severity may also influence outcomes, suggesting that patient characteristics matter when choosing between these interventions.
The Geriatric Evidence Gap Remains The Central Problem
The most important limitation is that much of the comparative evidence comes from mixed-age adult populations rather than trials designed specifically for older adults.
Lin and colleagues identified encouraging geriatric findings, including small studies suggesting that ketamine can produce substantial improvement while remaining tolerable in older patients. One case series involving adults between ages 67 and 94 reported high remission rates among participants receiving subcutaneous ketamine, with sustained benefits reported in some treatment completers.
These findings are promising, but small observational studies cannot establish that ketamine should replace ECT in geriatric practice. A recent systematic review of treatment-resistant late-life depression similarly concluded that relatively few randomized trials are available and that evidence quality varies considerably across interventions.
Cognitive Preservation Could Become A Major Decision Point
Cognition may be one of the most clinically relevant differences for older patients.
ECT can produce temporary cognitive effects, including memory difficulties, although individual experiences vary according to treatment parameters and patient factors. Ketamine does not carry the same established pattern of treatment-related memory impairment, potentially making it attractive when cognitive preservation is a major priority.
Ketamine introduces its own considerations, including transient dissociation and cardiovascular monitoring requirements. The comparison is therefore not between a treatment with risks and one without them. It is between interventions with different therapeutic profiles.
A More Personalized Framework For Advanced Depression Care
The emerging evidence suggests that ketamine and ECT may ultimately occupy complementary rather than competing roles.
ECT remains a critical intervention when depression is extremely severe, psychotic, or requires intensive treatment. Ketamine may provide an important alternative for selected patients seeking rapid symptom improvement without anesthesia, particularly in outpatient settings where cognitive preservation and treatment logistics influence decision-making.
For geriatric psychiatry, the next step is clear. Direct randomized trials focused specifically on older adults are needed to compare response, remission durability, cognition, medical safety, relapse, and quality of life.
Until those data arrive, ketamine vs ECT for geriatric depression should be viewed as an individualized clinical decision rather than a universal hierarchy. The goal is not simply to identify which intervention is more powerful, but to determine which treatment profile best matches the needs, risks, and priorities of each older adult.
Citations
- Lin A, Lall T, Simon S, Lee DY, Junquera P. Comparing Ketamine to Electroconvulsive Therapy in Geriatric Depression: Evidence, Gaps, and Clinical Implications. The American Journal of Geriatric Psychiatry. 2026. DOI: 10.1016/j.jagp.2026.03.156. ScienceDirect Article
- Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal of Medicine. 2023;388:2315-2325. DOI: 10.1056/NEJMoa2302399. New England Journal of Medicine Article
Explore more at https://www.interventionalpsychiatry.org/
